NeoGenomics Laboratories, Inc. (NEO)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$16.49-3.85%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
QuarterlyIQ Insights · NEO
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 787.8 | 727.3 | 660.6 | 591.6 | 509.7 | 484.3 | 444.4 | 408.8 | 276.7 | — | — | 5.0 | 5.0 | 5.0 | 5.0 | — |
| Cost of Revenues | 435.1 | 413.0 | 370.5 | 347.0 | 321.8 | 297.3 | 258.6 | 212.0 | 149.5 | — | — | — | — | — | — | — |
| Gross Profit | 352.7 | 314.3 | 290.1 | 244.6 | 187.9 | 187.1 | 185.9 | 196.8 | 127.3 | 102.0 | 98.1 | — | — | — | — | 19.4 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 39.3 | 37.1 | 31.2 | 27.3 | 30.3 | 21.9 | 8.2 | 8.5 | 3.0 | 3.6 | 4.6 | 4.2 | 2.7 | 2.4 | 2.3 | — |
| Operating Income | (49.4) | (115.9) | (92.1) | (107.7) | (157.6) | (118.8) | (14.0) | 13.0 | 10.0 | 2.9 | 2.2 | (5.6) | 2.2 | 3.2 | 1.2 | (0.4) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 3.8 | 6.6 | 6.9 | 7.6 | 8.2 | 7.0 | 3.7 | — | — | — | 0.9 | — | 1.0 | 1.1 | 0.8 |
| Interest & Investment Income | 5.2 | 9.1 | 18.4 | 16.9 | 6.1 | — | — | — | — | — | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | (10.0) | 1.5 | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | — | — | — | — | — | — | — | — | — | — | — | — | (0.9) | — | — | (0.8) |
| Asset Writedown | — | — | — | — | 0.7 | — | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | (36.2) | (110.3) | (80.7) | (97.1) | (159.3) | (15.1) | (14.1) | 3.6 | 3.8 | (2.7) | (7.8) | (4.5) | 1.3 | 2.2 | 0.1 | — |
| Income Tax Expense | (3.9) | (2.2) | (1.9) | (9.1) | (15.1) | (6.7) | (18.2) | (4.4) | 1.2 | (2.3) | (1.7) | (2.0) | 0.2 | 0.2 | 0.0 | — |
| Net Income | ||||||||||||||||
| Net Income | (32.3) | (108.0) | (78.7) | (88.0) | (144.0) | (8.0) | 4.2 | 8.0 | 2.6 | (0.4) | (6.1) | (2.5) | 1.1 | 2.0 | 0.1 | (1.2) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.25) | — | — | — | — | — | — | — | — | — | — | (0.04) | 0.02 | 0.04 | 0.00 | — |
| Diluted EPS | (0.25) | — | — | — | — | — | — | — | — | — | — | (0.04) | 0.02 | 0.04 | 0.00 | — |
| Revenue per Share | 6.13 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 128.6 | 128.1 | 126.7 | 125.5 | 124.2 | 120.0 | 108.6 | 100.5 | 85.6 | 79.4 | 77.5 | 60.5 | 53.5 | 48.3 | 45.0 | — |
| Diluted Weighted Avg Shares | 128.6 | 128.1 | 126.7 | 125.5 | 124.2 | 120.0 | 111.8 | 103.6 | 91.6 | 79.4 | 77.5 | 60.5 | 56.0 | 52.8 | 48.7 | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | — | 11.9 | 33.4 | 25.8 | 18.5 | 18.1 | 1.1 | 7.6 | — | — | — |
| EBIT | (49.4) | (115.9) | (92.1) | (107.7) | (157.6) | (118.8) | (14.0) | 13.0 | 10.0 | 2.9 | 2.2 | (5.6) | 2.2 | 3.2 | 1.2 | (0.4) |
| Effective Tax Rate | 10.7% | — | — | 9.4% | 9.5% | 44.6% | 129.7% | -119.6% | 31.0% | 85.1% | 21.7% | 43.5% | 12.2% | 7.0% | 0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.